Accessibility Statement Skip Navigation
  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing
  • Login
  • GDPR
  • Create a Free Account
Return to PRWeb homepage
  • News
  • Resources
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All News Releases
      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
  • Business & Money
      • Auto & Transportation

      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Advocacy Group Opinion
      • Animal Welfare
      • Congressional & Presidential Campaigns
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • U.S. State Policy
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Hamburger menu
  • Cision PRWeb provides efficient communication tools to continuously engage with target audiences across multiple online channels
  • Create a Free Account
    • ALL CONTACT INFO
    • Contact Us


      11AM ET Sunday – 8PM ET Friday

  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • News in Focus
    • Browse All News
    • Multimedia Gallery
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR

Find an Actos Bladder Cancer Allegations Lawyer: Resource4thePeople Notes Billion-Dollar Verdict Sought as Trial Gets Underway
  • USA - English


News provided by

iLawSuit

Mar 28, 2014, 03:00 ET

Share this article

Share toX

Share this article

Share toX

San Diego, CA (PRWEB) March 28, 2014 -- http://www.resource4thepeople.com/defectivedrugs/Actos-Bladder-Cancer-Lawsuit.html

Resource4thePeople today announced its latest update for consumers following litigation involving allegations that the use of Actos to treat diabetes can cause bladder cancer.

Among the most recent developments is continuing testimony in a Nevada trial* in which lawyers for two women are seeking over a billion dollars in damages over allegations that the women developed cancer because they used Actos to treat their diabetes.

The trial has been underway for several weeks with lawyers for two Clark County women in their 80s seeking compensatory and punitive damages against Takeda Pharmaceuticals, manufacturer of Actos (pioglitazone), according to the court file in the case.

"Due to Takeda Pharmaceutical’s conscious decision to keep this information from consumers and their doctors, we now have patients who are left to bear the permanent injury caused by Actos,” one of the plaintiffs' lawyers told the Las Vegas Review-Journal in a March 9, 2014 report.** “That’s why we will be asking for over a billion-dollar punitive damage verdict.”

The Nevada cases are among thousands of Actos lawsuits that have been filed over allegations of bladder cancer and the bulk of them, 2,923 cases,*** have been consolidated before a federal judge in Louisiana.

Those figures**** were compiled by the U.S. Judicial Panel on Multidistrict Litigation as of the latest reporting period ending March 13, 2014.

"The continued increase in the number of Actos lawsuits alleging that the medication may cause bladder cancer reflects the increasing number of inquiries we are receiving from consumers seeking information about their options to seek compensation over these allegations," said Resource4thePeople.

"Therefore we will continue to provide free consultations to consumers who are inquiring about whether they are eligible to file a lawsuit in connection with these allegations and are seeking experienced, aggressive legal representation."

Resource4thePeople is also informing consumers that it will keep them abreast of the latest development in litigation involving allegations in lawsuits that Actos may cause bladder cancer.

In other Actos litigation, another jury is continuing to hear evidence in the first federal bellwether trial***** selected from the nearly 3,000 cases in the Louisiana multidistrict litigation, according to the court file.

In that trial, a lawyer for man who claims he was diagnosed with cancer because of his use of Actos told jurors that the medication's manufacturers hid the risks of its Actos diabetes drug from consumers and doctors and should be held liable for the former shopkeeper’s cancer, according to a Feb. 3, 2014 Bloomberg News report.******

The plaintiff was prescribed Actos and used the product for about seven years, from 2004 until 2011, when he was diagnosed with bladder cancer, according to the court file in the case.

Resource4thePeople has found a significant increase in consumer interest about their legal options over bladder cancer allegations after the release of a June 15, 2011 Food and Drug Administration safety announcement.*******

The FDA safety announcement was issued after the agency reviewed a study sponsored by Takeda Pharmaceuticals which documented an increased risk of developing bladder cancer with Actos than other diabetes drugs.

Here is part of the safety announcement:

“The U.S. Food and Drug Administration (FDA) is informing the public that use of the diabetes medication Actos (pioglitazone) for more than one year may be associated with an increased risk of bladder cancer. Information about this risk will be added to the Warnings and Precautions section of the label for pioglitazone-containing medicines."

Two other trials outside this litigation were held in 2013 in which juries returned verdicts against Takeda Pharmaceuticals involving allegations that the medication can lead to bladder cancer.

In one case a Maryland jury awarded******** of $1.7 million to the family of a man who alleged that his use of Actos caused him to die of bladder cancer. That verdict was overturned after the judge found that the victim’s 30-year smoking habit contributed to his death.

The Maryland case was the second in which a jury found in favor of a plaintiff alleging that Takeda Pharmaceuticals was liable over bladder cancer but had the damages overturned on legal technicalities, according to court documents.

The Maryland case was preceded by one in California where a jury found in April that Takeda should pay $6.5 million in damages over similar allegations, according to the court file in that case.*********

Bloomberg News reported Sept. 26, 2013 that Takeda Pharmaceuticals, which is Asia's largest drug manufacturer, has been named in "more than 3,000 suits over the drug."**********

The report cited important facts about the Maryland case:

"A Maryland jury ruled that Takeda Pharmaceutical Co. (4502) didn’t properly warn an ex-U.S. Army translator and his doctor about the risks of its Actos diabetes drug and ordered the company to pay more than $1.7 million in damages. A judge immediately threw out the verdict.

"Jurors in state court in Baltimore deliberated more than six hours over two days before finding Asia’s largest drugmaker liable for the cancer death of Diep An, Michael Miller, one of An’s lawyers, said in an interview. Since jurors also found that An contributed to his death by smoking for 30 years, Judge Brooke Murdock set the verdict aside based on Maryland law."

Sources:
*Case # A-13-680556-C, Triana vs. Takeda Pharmaceuticals, Nevada District Court, Clark County
**http://www.reviewjournal.com/news/las-vegas-trial-starts-monday-multibillion-dollar-liability-case-against-diabetes-drug-maker
***In Re: Actos (Pioglitazone) Products Liability Litigation, MDL2299 U.S. District Court, Western District of Louisiana
****http://www.jpml.uscourts.gov/sites/jpml/files/Pending_MDL_Dockets_By_District-March-13-2014.pdf
*****Allen v. Takeda Pharmaceuticals North America, 12cv0064 U.S. District Court, Western District of Louisiana
******http://www.businessweek.com/news/2014-02-03/takeda-jury-told-officials-hid-diabetes-drug-s-cancer-risks-1
******* http://www.fda.gov/drugs/drugsafety/ucm259150.htm
********An v. Nieberlein, Case # 24-C12003565, Circuit Court for the City of Baltimore, State of Maryland
*********Cooper v. Takeda Pharmaceuticals America Inc., Case #CGC-12-518535, California Superior Court, Los Angeles
********** http://www.businessweek.com/news/2013-09-26/takeda-failed-to-properly-warn-about-actos-risks-jury-rules-1

Bill Callahan, iLawSuit, +1 858 602-2749, [email protected]

Modal title

Contact PRWeb

  • 11AM ET Sunday – 8PM ET Friday
  • Contact Us

About PRWeb

  • About PRWeb
  • Partners
  • Partnership Programs
  • Editorial Guidelines
  • Resources

Why PRWeb

  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing

Accounts

  • Create a Free Account
  • Log in
  • Contact Us

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921

Contact Cision

Products

About

My Services
  • All News Releases
  • Online Member Center
  • ProfNet
Cision Distribution Helpline
888-776-0942
  • Legal
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 Cision US Inc.